Login to Your Account



Backing a Potential Aesthetic Blockbuster

Fibrocell Brings in $22.8M to Launch Injectable laViv in U.S.

By Marie Powers


Wednesday, August 24, 2011
On Tuesday, Fibrocell Science Inc. appeared to swim against the tide of nervous capital markets, raising $22.8 million through a private placement of 41,409,458 shares of common stock at a purchase price of 55 cents per share.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription